Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

NCT ID: NCT01072565

Last Updated: 2015-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

91 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effectiveness of Self Monitoring of Blood Glucose (SMBG) for clinical decisions related to the management of type 2 diabetes and to determine the benefit of using Continuous Glucose Monitoring (CGM) for clinical diabetes management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SMBG Only

You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.

Group Type ACTIVE_COMPARATOR

SMBG to guide clinical decisions

Intervention Type OTHER

The investigator will base clinical decisions on A1c and modal day analysis of SMBG.

SMBG and CGM

You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.

Group Type ACTIVE_COMPARATOR

SMBG and CGM

Intervention Type OTHER

The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SMBG to guide clinical decisions

The investigator will base clinical decisions on A1c and modal day analysis of SMBG.

Intervention Type OTHER

SMBG and CGM

The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects ≥18 and ≤75 years of age
* Clinical diagnosis of diabetes
* Diabetes duration ≥ 1 year
* HbA1c ≥7.2%
* Diabetes can be treated with any therapy including medical nutrition therapy alone and any pharmaceutical therapy

Exclusion Criteria

* Taken prednisone or cortisone medications in the previous 30 days
* Currently pregnant or planning pregnancy during the study period
* Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study
* Unable to follow the study protocol
* Unable to speak, read and write in English
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

International Diabetes Center at Park Nicollet

OTHER

Sponsor Role collaborator

Abbott Diabetes Care

INDUSTRY

Sponsor Role collaborator

HealthPartners Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roger S Mazze, PhD

Role: PRINCIPAL_INVESTIGATOR

International Diabetes Center at Park Nicollet

Elinor S Strock, APRN, BC

Role: PRINCIPAL_INVESTIGATOR

International Diabetes Center at Park Nicollet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

International Diabetes Center

Minneapolis, Minnesota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

03914-09-C

Identifier Type: -

Identifier Source: org_study_id